BioWorld

May 23, 2006

View Archived Issues

Adventrx Moves Into Phase III With CoFactor, Pulls Offering

Adventrx Pharmaceuticals Inc. and the FDA have agreed on a special protocol assessment for a Phase III trial of its chemotherapy enhancing drug, CoFactor, expected to start this quarter. (BioWorld Today) Read More

U3 Pharma Raises €27M For Preclinical Cancer Products

No Abstract Read More

ImaRx Seeking $75M IPO For Anti-Clotting Products

Read More

SEC Signaling Interest In Scaling Back SOX Rules

Read More

Naryx Series B2 Financing Gets $8M For Chronic Sinusitis Drug

Read More

Clinic Roundup

Read More

Other News To Note

Read More

Appointments And Advancements

Read More